Start here if you're new
what it is
Minerva is a brain-disease biotech with 3 drug candidates and no approved product.
how it gets paid
Last year Minerva Neuroscience made $0 in revenue.
what just happened
The latest quarter looked like a lab invoice: $0 revenue and -$1.29 EPS.
At a glance
C balance sheet — red flag territory — real financial stress
10/100 earnings predictability — expect surprises
1.4x trailing p/e — the market's not buying it — or you found a deal
3.7% return on capital — nothing to write home about
$0.19 fy2024 eps est
xvary composite: 25/100 — weak
What they do
Minerva is a brain-disease biotech with 3 drug candidates and no approved product.
You are buying 8 employees and 3 shots on goal. Roluperidone, MIN-301, and seltorexant are all unapproved, so 0 commercial sales means the whole stock still sits on FDA decisions. Eight people doing this work is absurd, but 1 approval would change the math fast.
How they make money
$0
annual revenue
The products that matter
lead schizophrenia candidate
Roluperidone
core thesis
This is the program carrying the $339M equity story. With only $41M in annual revenue on the page, the stock still needs clinical proof more than it needs narrative.
lead asset
commercialization question
Regulatory path
still unresolved
For NERV, approval matters more than modeling. A 10/100 predictability score tells you the business is still shaped by milestones, not operating consistency.
catalyst path
funding capacity
Balance sheet
$60M long-term debt
This is not a side note. A company with $60M in long-term debt and a C strength grade does not get unlimited time to wait for the perfect data date.
time limit
Key numbers
$0
revenue
No sales means every valuation dollar is still a bet on trials.
8
employees
Eight people are carrying a public biotech.
1.4x
trailing p/e
The market pays 1.4x earnings for a company with no commercial product.
$60M
debt
Debt equals 15% of capital, which is heavy for a pre-revenue company.
Financial health
C
strength
- balance sheet grade C — very weak — significant financial distress
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $60M (15% of capital)
C — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for NERV right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The latest quarter looked like a lab invoice: $0 revenue and -$1.29 EPS.
EDGAR says annual revenue was $0. The company is still funding 3 clinical programs, not selling one.
$0
revenue
$1.29
eps
4.9%
operating margin
sales
The $0 revenue number matters because the stock is still a trial bet, not a product story.
source: EDGAR quarterly filing, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is clinical failure or delay for roluperidone. This is a single-story biotech, and single-story biotechs do not get many bad chapters.
med
roluperidone does not de-risk
If the lead program fails clinically, stumbles with regulators, or simply takes longer than expected, the equity case loses its center of gravity. There is no diversified operating base here to absorb that.
That would hit the one asset supporting a ~$339M market cap while the rest of the business shows just $41M in annual revenue.
med
financing pressure arrives before proof
A C balance sheet and $60M in long-term debt mean time is not free. If the next meaningful catalyst slips, capital may need to arrive before investor confidence does.
More financing on a weak setup can dilute the existing equity even if the science remains intact.
med
commercial upside proves smaller than hoped
Even a successful drug is not automatically a great stock. The market still has to believe the product can be approved, reimbursed, and sold into a real niche.
That matters because a 1.4x trailing p/e and $0.19 EPS estimate do not give you a dependable fallback valuation framework.
With $41M in annual revenue, $60M in long-term debt, and a C balance sheet, Minerva does not have much room for a failed catalyst and a financing event at the same time.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
the next material roluperidone update
This is the date that matters. In a company with 10/100 predictability, the calendar is doing more work than the income statement.
risk
balance sheet strain
Keep one eye on the C strength grade and the other on the $60M debt load. If the timeline stretches, financing risk gets louder.
metric
earnings predictability
10/100 is the market telling you the operating picture is still unstable. If that number does not improve, traditional valuation stays weak.
trend
price vs. conviction
A stock that traded from $1 to $12 in a year can move faster than the fundamentals update. Watch whether price moves on better evidence or just louder hope.
Analyst rankings
short-term outlook
mixed
coverage is thin and target data is weaker than usual. in human-speak: there is no crowd consensus to hide behind.
risk profile
volatile
a 5 / 100 price stability score tells you this name trades on events, not calm compounding.
chart momentum
catalyst-led
the 52-week range of $1–$12 says price action is reacting to changing belief, not a smooth operating trend.
earnings predictability
10 / 100
for a normal company this would be a warning. for a clinical biotech, it is the whole setup in one number.
source: institutional data
Institutional activity
institutional ownership data for NERV is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$4
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive